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Background: Significant progress has been made to increase access to vaccines in Africa since the 1974
launch of the Expanded Programme on Immunization (EPI). Successes include the introduction of several
new vaccines across the continent and likely eradication of polio. We examined the contribution of polio
eradication activities (PEI) on new vaccine introduction in the countries of the African Region.
Methods: We reviewed country specific PEI reports to identify best practices relevant to new vaccine
introduction (NVI), and analyzed trends in vaccine coverage during 2010–2015 from immunization esti-
mates provided by WHO/UNICEF.
Results: Of the 47 countries in African Region 35 (74%) have introduced PCV, 27 (57%) have introduced
rotavirus, and 14 (30%) have introduced IPV. National introductions for HPV vaccine have been done in
5 countries, while 15 countries have held demonstration and pilot projects. In 2014, the regional coverage
for the third dose of PCV (PCV3) and rotavirus vaccines was 50% and 30% respectively. By end of 2015, all
countries within the meningitis belt will have introduced MenAfriVacTM vaccine.
Conclusions: PEI activities had a positive effect in strengthening the process of new vaccine introduction
in the African Region. The major contribution was in availing immunization funding and providing
trained and experienced technical staff to introduce vaccines. More investment is needed to advocate
and sustain funding levels to maintain the momentum gained in introducing new vaccines in the region.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In 1974, the World Health Organization (WHO) launched the
Expanded Program on Immunization (EPI) to fight six vaccine-
preventable diseases (diphtheria, measles, pertussis, poliomyelitis,
tetanus, tuberculosis) through routine infant immunization [1].
Since then several international efforts to increase EPI coverage
have been adopted, including the Gavi Alliance and most recently
the Global Vaccine Action Plan (GVAP) 2011–2020 which aims to
increase universal access to vaccines in all parts of the world by
strengthening routine immunization (RI), advancing research and
introducing new and improved vaccines to tackle more vaccine-
preventable diseases [2]. These initiatives, coupled with regional
efforts such as the WHO African Region’s (AFR) vaccine action plan
2014–2020 (RVAP) and the Reach Every District (RED) approachhave led to significant improvements in the performance of the
EPI programme in the 47 member WHO African region (AFR)
though country variability exists. Regional coverage with three
doses of the diphtheria-tetanus-pertussis which is given by
12 months of age (DTP3) rose from 5% in 1974 to 77% in 2014
[3,4]. Moreover, there has been significant progress in the intro-
duction of new and underutilized vaccines in Africa, especially in
the recent past. These vaccines include hepatitis B birth dose
(HepB-BD), Haemophilus influenza type b (Hib), pneumococcal con-
jugate (PCV), rotavirus, and those targeting older age–age groups
or specific demographic e.g., human papilloma virus (HPV) and
meningococcal group A conjugate vaccine (MenAfriVacTM).
Optimal vaccine introduction requires a strong planning pro-
cess that is integrated within RI programmes with well-trained
workforce, functional cold chain, logistics and vaccine manage-
ment system, and system for safe immunization practices and
monitoring of adverse events [5]. Studies have found new vaccine
introduction (NVI) to be most efficient when the vaccine is
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for other EPI antigens, or when combined with another childhood
vaccine [6]. NVI can have both positive and negative impact on the
overall national immunization programme and the country’s
health system [7]. On one hand NVI provides an opportunity to
strengthen immunization and health systems, while on the con-
trary NVI, especially in countries with weak systems may ‘stress’
existing programmes and hamper their ability to meet global per-
formance indicators [8]. This strain is compounded by ongoing
health initiatives e.g., Global Polio Eradication Initiative (GPEI).
Moreover, the Polio Eradication and Endgame Strategic Plan
2013–2018 calls on countries to introduce at least one dose of inac-
tivated poliovirus vaccine (IPV) into their RI programmes [9]. Crit-
ics accuse disease-specific health initiatives of burdening weak
health systems in countries with limited resources further pre-
venting them from meeting disease-specific targets [8,10].
Significant progress has been made since the 1988 launch of the
GPEI and only Afghanistan and Pakistan remain that have not
interrupted wild poliovirus (WPV) transmission [11]. The African
region is much closer to eradicating polio with the removal of
Nigeria from the list of polio-endemic countries [12]. Prior to this,
Nigeria and Northern Nigeria in particular had been identified as a
reservoir for WPV cases that were reintroduced into 26 previously
polio-free countries in AFR resulting in large international out-
breaks [13]. These outbreaks led to intensified polio eradication
activities in AFR to interrupt WPV transmission in Nigeria and con-
trol the polio outbreaks by improving surveillance and conducting
several supplemental immunization campaigns (SIAs) [14].
The high level of polio eradication activities (PEI) in AFR have
raised discussions as to whether the GPEI has contributed to
improved roll out of new vaccines in the region [10]. Evidence on
this topic in AFR is mainly anecdotal and limited studies exist. This
paper reviews NVI in the African Region during 2010–2015 and the
contribution if any provided by PEI. Particular consideration is
given to countries that had significant PEI activities in the same
time-period because of their risk of WPV transmission.2. Methods
We searched online databases and peer review journals rele-
vant to vaccination and immunization to identify articles and
reports with information on NVI and PEI activities in AFR during
2010–2015. WHO and United Nations Children’s Fund (UNICEF)
estimates of national infant immunization coverage were retrieved
from the WHO-EPI information system which consists of data
reported to the WHO AFR office by each Member State annually
[15]. The trend in coverage of new vaccines was analyzed from
the period following introduction to the most recent year for which
full routine coverage data are available.
Information on PEI activities in AFR during 2010–2015 was
retrieved from GPEI databases and relevant peer review papers.
Best practices from PEI that correlated with NVI during the same
time period were identified from a review of country-specific doc-
uments that described lessons learnt from PEI implementation as
part of polio legacy planning and endgame strategy in AFR. We
reviewed documents from six countries (Angola, Chad, Cote
D’Ivoire, Ethiopia, the Democratic Republic of Congo (DRC), Tanza-
nia, and Togo) and identified two relevant best practices.
PEI supported infrastructure and human resources were critical
in rolling out new vaccines in the selected countries and AFR as a
whole. The financial support provided by the PEI initiative enabled
technical staff to be recruited increasing the immunization work-
force in the region. Polio-funded staffs were primarily located at
the country or district level and held key positions within EPI
and administration. They often served as EPI mangers and wereresponsible for supporting all national immunization activities,
including NVI. Polio support was key in Angola and helped allevi-
ate a countrywide scarcity of health workforce.
PEI procured several assets and infrastructure to enable coun-
tries conduct and monitor numerous rounds of polio SIAs. Man-
agers in Ethiopia, Cote D’Ivoire, Congo and Togo utilized these
assets to also monitor NVI in addition to the support provided by
the Gavi Alliance. Moreover, trainings for health workers on polio
surveillance and prevention were utilized as platforms to reinforce
the information on new vaccines. Managers also incorporated
messages on new vaccines in polio-information education and
communication (IEC) materials and training manuals.
PEI conducted extensive research and developed innovative
strategies to identify and reach children in hard-to-reach areas
with oral polio vaccine (OPV). Most of these remote areas had a
high number of unvaccinated children and women of childbearing
ages. Identifying these remote settlements and villages provided
information to immunization managers who included them for
planning for new vaccines. The numerous polio SIAs conducted
in AFR provided EPI managers with invaluable experience in con-
ducting vaccination campaigns, which was previously lacking in
the region. PEI-led initiatives to improve district-level planning
and microplans helped guide and inform NVI. Lessons learnt from
planning for polio campaigns were incorporated in the microplan-
ning section of the New Vaccine Checklist developed by WHO to
assist countries in making informed decisions about adding new
vaccines and guided the planning of smooth vaccine introduction
[5]. This polio support to improving campaigns was especially
relevant to MenAfriVacTM that was rolled out through mass
vaccination campaigns in countries of the African meningitis belt,
including Chad, Cote d’Ivoire, DRC, and Ethiopia.
In Chad, MenAfriVacTM was rolled out through several multi-
phase campaigns conducted countrywide. Health staff used a
model that is similar to that used during polio SIAs to access
hard-to-reach villages and provided the vaccine in a combination
of fixed, mobile, and outreach strategies.
In Togo, PEI funds initiated and continue to support district
level microplanning for new vaccines before their integration into
routine immunization.3. Results
Several countries introduced new vaccines during 2010–2015.
By November 2015, 35 (74%) of the 47 countries in AFR had intro-
duced PCV into their national immunization programmes and four
more plan to introduce (Fig. 1). For rotavirus vaccine, 27 (57%) of
countries in the region had introduced the vaccine and two more
are planned for this year. Since the 2013 Human Papillomavirus
Virus (HPV) demonstration project in Kenya, more countries in
the region have rolled out the vaccine. National introductions for
HPV vaccine have been done in five countries: Botswana, Lesotho,
Rwanda, Seychelles and South Africa, while 15 countries are carry-
ing out demonstration and pilot projects (Fig. 1). Uganda has been
approved for nationwide introduction in 2015. To date, 14 (30%)
countries in the AFR region have introduced IPV (Fig. 1) although
several have finalized plans to introduce the vaccine and are limited
by the global shortage in vaccine supply. Table 1 provides a sum-
mary of the number and type of new vaccines that have been intro-
duced in African countries during 2010–2015. In 2014, the regional
coverage for the third dose of PCV (PCV3) and rotavirus vaccines,
both of which are in the EPI schedule was 50% and 30% respectively.
By end of 2015, all countries within the meningitis belt will
have introduced MenAfriVacTM through vaccines (Fig. 2). High qual-
ity mass vaccination campaigns were carried out in Ethiopia and
Nigeria. These countries were concurrently reporting WPV cases
* 35/47 Countries : Angola, Benin, Botswana, 
Burkina Faso, Burundi, Cameroon, Congo, 
Cote d’Ivoire, Central Afr Rep, DRC, Ethiopia, 
Gambia, Guinea Bissau Mauritania, Ghana, 
Kenya, Liberia, Madagascar, Malawi, Mali, 
Mozambique, Namibia, Niger, Nigeria, 
Rwanda, STP, Senegal, Sierra Leone, South 
Africa, Swaziland, Tanzania, Togo, Uganda,  
Zambia, Zimbabwe
*27/47 Countries : Angola, Botswana, 
Burkina Faso, Burundi, Cameroon, Congo, 
Eritrea, Ethiopia, The Gambia, Ghana, 
Kenya, Madagascar, Malawi, Mali, 
Mauritania, Mauritius, Mozambique, 
Namibia, Niger, Rwanda, Senegal, Sierra 
Leone, South Africa, Tanzania, Togo, 
Zambia, Zimbabwe
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Fig. 1. Status of new vaccine introduction in AFR as of November 2015. *WHO/AFRO/FRH/IVD database.
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to improve poliovirus surveillance in the AFR to address surveil-
lance gaps. This entailed improving technical staff capacity atcountry level, and buffing up polio infrastructure and assets. Of
the total number of EPI ‘‘core” staff, 94% were polio-funded, of
whom approximately 70% are located in six countries, including
Table 1
African Countries that have introduced PCV, Rota and HPV in the National Immunization Programme, as of October, 2015. Source: WHO Immunization Repository.
Country Income level GAVI eligibility status Vaccines Intro year
Algeria Upper middle income Not eligible PCV 2015
Angola Upper middle income Graduate PCV 2013
Rota 2014
Benin Low income Eligible PCV 2011
Botswana Upper middle income Not eligible PCV 2012
Rota 2012
HPV 2015
Burkina Faso Low income Eligible PCV 2013
Rota 2013
Burundi Low income Eligible PCV 2011
Rota 2013
Cameroon Lower middle income Eligible PCV 2011
Rota 2014
Central African Republic (the) Low income Eligible PCV 2011
Rota 2016
Chad Low income Eligible Rota 2017
Comoros (the) Low income Eligible PCV 2016
Rota 2016
Congo (the) Lower middle income Graduate PCV 2012
Rota 2014
Cote d’Ivoire Lower middle income Eligible PCV 2014
Rota 2015
DR Congo Low income Eligible PCV 2011
Equatorial Guinea High income: non-OECD Not eligible PCV 2015
Eritrea Low income Eligible PCV 2015
Rota 2014
Ethiopia Low income Eligible PCV 2011
Rota 2013
Gabon Upper middle income Not eligible PCV 2015
Rota 2017
Gambia (the) Low income Eligible PCV 2009
Rota 2013
Ghana Lower middle income Graduate PCV 2012
Rota 2012
Guinea-Bissau Low income Eligible PCV 2015
Rota 2015
Kenya Lower Middle Income Eligible PCV 2011
Rota 2014
Lesotho Lower middle income Eligible PCV 2015
Rota 2016
HPV 2009a
Liberia Low income Eligible PCV 2014
Rota 2016
Madagascar Low income Eligible PCV 2012
Rota 2014
Malawi Low income Eligible PCV 2011
Rota 2012
Mali Low income Eligible PCV 2011
Rota 2014
Mauritania Lower middle income Eligible PCV 2013
Rota 2014
Mozambique Low income Eligible PCV 2013
Rota 2015
Namibia Upper middle income Not eligible PCV 2014
Rota 2014
Niger (the) Low income Eligible PCV 2014
Rota 2014
Nigeria Lower middle income Graduate PCV 2014
Rota 2017
Rwanda Low income Eligible PCV 2009
Rota 2012
HPV 2014
Sao Tome and Principe Lower middle income Eligible PCV 2012
Rota 2016
Senegal Lower middle income Eligible PCV 2013
Rota 2014
Seychelles High income: non-OECD Not eligible PCV 2017
HPV 2014
Sierra Leone Low income Eligible PCV 2011
Rota 2014
South Africa Upper middle income Not eligible PCV 2008
Rota 2008
HPV 2014
5196 M. Carole Tevi-Benissan et al. / Vaccine 34 (2016) 5193–5198
Table 1 (continued)
Country Income level GAVI eligibility status Vaccines Intro year
Swaziland Lower middle income Not eligible PCV 2014
Rota 2015
Togo Low income Eligible PCV 2014
Rota 2014
Uganda Low income Eligible PCV 2013
Rota 2016
United Republic of Tanzania (the) Low income Eligible PCV 2013
Rota 2013
Zambia Lower middle income Eligible PCV 2013
Rota 2012
Zimbabwe Low income Eligible PCV 2012
Rota 2014
a Demonstration project.
Fig. 2. African countries that have introduced MenAfriVacTM vaccine, 2015. *WHO/AFRO/FRH/IVD database.
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nization staff infrastructure, 86% are polio-funded. These staff
enabled the implementation of quality SIAs for MenAfriVacTM vac-
cine in Ethiopia and Chad.
4. Discussion
In this review, we found that polio eradication activities con-
tributed positively to the process of introducing new vaccines in
Africa. Polio support to NVI was mainly by availing, highly trained
polio-supported technical staff with extensive field experience to
coordinate activities in the country, and providing opportunities
to retrain health staff on new vaccine knowledge and administra-
tion. African countries often facing limited resources and a high
volume of new vaccines can place a major burden on cold chain
and logistic capacity of EPI programs, many of whom have already
pre-existing challenges with sustaining capacity of traditional vac-
cine antigens. In addition, vaccine introduction oftentimes requires
additional staff or adjustment in routine immunization schedule
and lack of staff has been reported as a barrier to new vaccine
introduction other countries [7].
Integrating NVI with polio eradication activities utilized
resources for both programmes efficiently making the whole pro-
cess cost-effective, improved the quality, and was well accepted
by governments. In fact, NVI benefited from lessons learnt and
gains of PEI. A well performing technically sound health workforcewith sufficient numbers of staff who are equitably distributed is
vital to achieve good health systems necessary for introducing
new vaccines [5]. Use of highly trained and experienced PEI sup-
ported polio field officers to launch new vaccines, made the pro-
cess easier leading to higher coverage of new vaccines within a
very short time. Lessons learnt from conducting previous polio SIAs
ensured successful roll-out of MenAfriVacTM vaccine in AFR. A lim-
itation of our review is that the selected countries all had polio
eradication activities, and their experience might be different from
NVI in countries with no PEI activities.
Despite the progress in introducing new vaccines in AFR, many
African countries remain that have not introduced the available
new vaccines, and those that have introduced still need to increase
their coverage. Furthermore, with the global advancement in
developing new vaccine, more sophisticated vaccines have become
available and they need to be introduced in Africa in a timely man-
ner and avoid the lag between high and low-income countries. The
high cost of rolling out new vaccines and donor or co-payments
required places additional burden for limited resources. The Gavi
Alliance has spearheaded efforts to increase funding for immuniza-
tion and increase availability of new vaccines to low-resource eli-
gible countries. The challenge however lies in making these
vaccines accessible to middle-income countries that do not qualify
for financial support.
NVI should be viewed as an opportunity to strengthen immu-
nization systems, increase vaccine coverage and reduce inequities
5198 M. Carole Tevi-Benissan et al. / Vaccine 34 (2016) 5193–5198of access to immunization services. PEI successes in AFR were
achieved by ensuring sustainable financing for immunization focus
areas in countries identified by their performance levels and not
economic categories. With the success of PEI and Nigeria being
declared polio-free, there will be an eventual decline on polio
funds which increases the risk of negating the progress witnessed
in the recent past. It therefore falls on governments and immuniza-
tion stakeholders to advocate and maintain funding levels and
infrastructure, so that the momentum gained in introducing new
vaccines over the past 5 years is not lost.Conflict of interest
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